Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 -- (Healthcare Sales & Marketing Network) -- Sat... Biopharmaceuticals, Drug Delivery, Venture Capital Satsuma Pharmaceuticals, dihydroergotamine, nasal powder, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news